机构地区：[1]área de Toxicología, Departamento de Ciencias Biológicas, Facultad de Ciencias Exactas, Universidad Nacional de La Plata, La Plata, Provincia de Buenos Aires, Argentina [2]Laboratorio UPL, Universidad Nacional de La Plata/Comisión de Investigaciones Científicas de la Provincia de Buenos Aires, La Plata, Argentina [3]Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), La Plata, Argentina [4]Instituto Multidisciplinario de Investigaciones en Patologías Pediátricas (IMIPP-CONICET), Servicio de Parasitología y Chagas, Hospital de Niñ os “Dr. Ricardo Gutiérrez”, Buenos Aires, Argentina [5]Division of Paediatric Clinical Pharmacology, Department of Paediatrics, Schulich School of Medicine and Dentistry, Western Ontario University, London, Ontario, Canada
出 处：《Pharmacology & Pharmacy》2021年第8期155-166,共12页药理与制药（英文）
摘 要：<span style="font-family:""><span style="font-family:Verdana;">Infection with </span><i><span style="font-family:Verdana;">Toxoplasma gondii</span></i><span style="font-family:Verdana;">, is one of the most widespread zoonoses in the world. Congenital Toxoplasmosis (CT) is particularly risky due to its fetal </span><span style="font-family:Verdana;">complications. Sulfadiazine (SDZ) and Pyrimethamine (PYR) are usually </span><span style="font-family:Verdana;">used </span><span style="font-family:Verdana;">for CT treatment in Argentina, to prevent morbidity. Due to the lack of </span><span style="font-family:Verdana;">commercial pediatric formulations, these must be prepared in the hospital pharmacy. This is the first report of serum concentrations measures in pediatric CT therapy for this combination of drugs. A bioanalytical method was developed for identification and simultaneous quantification of SDZ and PYR by High Performance Liquid Chromatography (HPLC) with UV detection. The validated method was applied to residual serum samples obtained from 6 pediatric patients undergoing treatment with SDZ 42.20 a 93.70 mg/kg/day and </span><span style="font-family:Verdana;">PYR 0.77 a 2.70 mg/kg/day. Sample pretreatment consisted </span></span><span style="font-family:Verdana;">on</span><span style="font-family:Verdana;"> a</span><span style="font-family:""><span style="font-family:Verdana;"> deproteini</span><span style="font-family:Verdana;">zation step followed by centrifugation and then injection of supernatant.</span><span style="font-family:Verdana;"> Limit of Detection (LOD) and Quantification (LOQ) were (0.17 ± 0.02 and 0.13 ± 0.02) μg/mL and (0.46 ± 0.01 and 0.36 ± 0.01) μg/mL for SDZ and PYR respectively, with an appropriate linear range. Concentrations range found </span><span style="font-family:Verdana;">were (<LOD</span></span><span style="font-family:Verdana;"> - </span><span style="font-family:Verdana;">162.04 ± 0.02) μg/mL for SDZ and (<LOD</span><span style="font-family:Verdana;"> - </span><spa<span style="font-family:""><span style="font-family:Verdana;">Infection with </span><i><span style="font-family:Verdana;">Toxoplasma gondii</span></i><span style="font-family:Verdana;">, is one of the most widespread zoonoses in the world. Congenital Toxoplasmosis (CT) is particularly risky due to its fetal </span><span style="font-family:Verdana;">complications. Sulfadiazine (SDZ) and Pyrimethamine (PYR) are usually </span><span style="font-family:Verdana;">used </span><span style="font-family:Verdana;">for CT treatment in Argentina, to prevent morbidity. Due to the lack of </span><span style="font-family:Verdana;">commercial pediatric formulations, these must be prepared in the hospital pharmacy. This is the first report of serum concentrations measures in pediatric CT therapy for this combination of drugs. A bioanalytical method was developed for identification and simultaneous quantification of SDZ and PYR by High Performance Liquid Chromatography (HPLC) with UV detection. The validated method was applied to residual serum samples obtained from 6 pediatric patients undergoing treatment with SDZ 42.20 a 93.70 mg/kg/day and </span><span style="font-family:Verdana;">PYR 0.77 a 2.70 mg/kg/day. Sample pretreatment consisted </span></span><span style="font-family:Verdana;">on</span><span style="font-family:Verdana;"> a</span><span style="font-family:""><span style="font-family:Verdana;"> deproteini</span><span style="font-family:Verdana;">zation step followed by centrifugation and then injection of supernatant.</span><span style="font-family:Verdana;"> Limit of Detection (LOD) and Quantification (LOQ) were (0.17 ± 0.02 and 0.13 ± 0.02) μg/mL and (0.46 ± 0.01 and 0.36 ± 0.01) μg/mL for SDZ and PYR respectively, with an appropriate linear range. Concentrations range found </span><span style="font-family:Verdana;">were (<LOD</span></span><span style="font-family:Verdana;"> - </span><span style="font-family:Verdana;">162.04 ± 0.02) μg/mL for SDZ and (<LOD</span><span style="font-family:Verdana;"> - </span><spa
关 键 词：TOXOPLASMOSIS BIOANALYTICS Pediatric Pharmacology Therapeutic Drug Monitoring Neglected Diseases
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
